DVAX - Dynavax Technologies Corporation
11.64 0.00 (0.00%)
After hours: 4:56PM EST
| Previous Close | 10.82 |
| Open | 10.98 |
| Bid | 11.42 x 2900 |
| Ask | 12.15 x 3200 |
| Day's Range | 10.84 - 11.68 |
| 52 Week Range | 9.63 - 22.80 |
| Volume | 814,267 |
| Avg. Volume | 1,173,170 |
| Market Cap | 729.729M |
| Beta (3Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.36 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.60 |
- Thomson Reuters StreetEvents•22 days ago
Edited Transcript of DVAX earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 Dynavax Technologies Corp Earnings Call
- Motley Fool•last month
Why Dynavax Technologies Corporation Fell 20.2% in October
Preliminary data that looked good on the surface left investors with more questions than answers.
- Associated Press•last month
Dynavax Technologies: 3Q Earnings Snapshot
The Berkeley, California-based company said it had a loss of 65 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
Conference Call to be held Today at 4:30pm ET/1:30pm PT BERKELEY, Calif., Nov. 05, 2018 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for.
- Motley Fool•last month
Don't Waste Your Money on Penny Stocks; These 3 Stocks Are Better Buys
If you're looking for high-reward stocks, these three could pay off big.
- GlobeNewswire•last month
Dynavax to Host Third Quarter 2018 Financial Results Conference Call
BERKELEY, Calif., Oct. 29, 2018 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September.
- Zacks•2 months ago
Dynavax Technologies (DVAX) Q3 Earnings Preview: What to Watch Ahead of the Release
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•2 months ago
Dynavax (DVAX) Catches Eye: Stock Jumps 9.8%
Dynavax (DVAX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Motley Fool•2 months agoWhy American Railcar Industries, PetMed Express, and Dynavax Technologies Jumped Today
Find out which of these companies got a buyout bid.
- Motley Fool•2 months ago
Why Dynavax Technologies Corporation Is Surging Today
Encouraging clinical data helps the beaten-down biotech to recover.
- GlobeNewswire•2 months ago
Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative.
- ACCESSWIRE•2 months ago
Medical Companies You Need to Have on Your Radar
HENDERSON, NV / ACCESSWIRE / October 18, 2018 / Below are a few Medical stocks that are in position to make their investors major profit in the coming sessions.The company on our radar today, however, ...
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
Dynavax Technologies Corporation (DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the immunotherapy combination of Dynavax’s proprietary investigational compound SD-101 and KEYTRUDA® (pembrolizumab) will be evaluated in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer. SD-101 is expected to augment responses to anti-PD-1 therapy as has been reflected in early clinical studies of other tumor types.
- Benzinga•2 months ago
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, ...
- ACCESSWIRE•2 months ago
Major Biotech Announcements Moving the Market
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
- InvestorPlace•2 months ago
ARWR Stock Sinks After Signing a Big Collaboration Deal
On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).
- GlobeNewswire•2 months ago
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
BERKELEY, Calif., Oct. 09, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating.
- Motley Fool•2 months ago
Why Dynavax Technologies Corporation Stock Struggled in September
Dynavax's shares kept losing ground last month, but a turnaround could be close at hand.
American City Business Journals•2 months agoHealth Care Digest: An East Bay biotech coup, a Nobel effort and an A's bobblehead
Nobel Prize winner Jim Allison is in Texas, but the Nobel Prize win Monday for his cancer immunotherapy work reverberates in the Bay Area.
- Motley Fool•2 months ago
3 Top Stocks That Aren't on Wall Street's Radar
From two intriguing small-cap stocks to a large-cap play, here are three stocks calling for your attention.
- GlobeNewswire•2 months ago
Dynavax to Present at the 2018 Cantor Global Healthcare Conference
BERKELEY, Calif., Sept. 27, 2018-- Dynavax Technologies Corporation today announced that Eddie Gray, Dynavax’ s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on ...
